Special Issue

PROTACs as Dual Motif Dmall Molecule Drugs: Past, present and future of Targeted Protein Degradation in Development

Message from the Guest Editors

In this Special Issue, we invite researchers to submit their latest research findings or review articles related to PROTAC-type molecules and other multiple targeting single molecule drugs for treatment of cancer and other diseases. Different classes of ligands for target protein binding, E3 ligase binding, and chain length of the spacers will be helpful for readers/researchers in this type of drug development, and hence, we encourage submissions discussing these aspects as well. Apart from conventional bifunctional target protein degraders, we invite articles based on molecular glues, large molecule-based degraders, and other less common unconventional degraders.

Guest Editors

Dr. Sridhar Radhakrishnan

Dr. Li Chai

Prof. Dr. Daniel G. Tenen

Dr. Susumu Kobayashi

Deadline for manuscript submissions

closed (1 November 2022)



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



mdpi.com/si/41384

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/ molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

